市場調査レポート

商品コード

1588513

細胞株開発の市場規模、シェア、成長分析、製品タイプ別、供給源別、用途別、地域別 - 産業予測、2024年～2031年

Cell Line Development Market Size, Share, Growth Analysis, By Product, By Source, By Type, By Application, By Region - Industry Forecast 2024-2031

出版日: 2024年11月05日
発行: SkyQuest
ページ情報: 英文 203 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

細胞株開発の世界市場規模は、2022年に47億米ドルと評価され、2023年の51億6,000万米ドルから2031年には109億4,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは9.84％で成長する見通しです。

細胞株開発市場は、同分野の急速な進歩とともに、革新的な細胞技術や製品への投資が増加していることを背景に、大きな成長が見込まれています。個別化医療に対する世界の需要の高まりは、細胞研究への投資の高まりと相まって、この分野のプロバイダーに新たな機会をもたらしています。さらに、様々な疾病に対処するためのバイオシミラーや生物製剤に対するニーズの高まりは、細胞株開発企業の将来性をさらに高めると予想されます。ヘルスケアの成果を向上させることを目的とした新規医薬品、治療薬、ワクチンの創出に注力することで、今後数年間はこの分野の需要が刺激される可能性が高いです。さらに、遺伝子編集技術の急速な応用は、細胞株開発を専門とする企業に有利な展望をもたらします。しかし、高い開発コスト、倫理的ジレンマ、スケーラビリティのハードルなどの課題は、予測期間中およびそれ以降を通じて市場成長の潜在的な障壁となります。全体として、細胞株開発市場はいくつかの課題に直面しているもの、技術の進歩の融合、高度な医療ソリューションに対する需要の増加、ヘルスケアにおけるイノベーションの継続的な追求により、成長と機会のための強固な環境が整いつつあります。

市場概要
機器別
- バイオセーフティキャビネット
- 細胞カウンターと生存率分析システム
- インキュベーター
- 遠心分離機
- バイオリアクター
- 保管設備
- 冷蔵庫・冷凍庫
- 冷凍保存システム
- 自動化システム
- 顕微鏡
- 濾過システム
- その他の機器
培地と試薬別
- 血清
- ウシ胎児血清（FBS）
- 成牛血清（ABS）
- その他の動物血清
- 培地
- 最低限必要な培地（MEM）
- 還元血清培地
- 無血清培地（SFM）
- 試薬
- サプリメントと成長因子
- 緩衝剤と化学薬品
- 細胞分離試薬
- 凍結保存試薬
- その他の試薬

細胞株開発市場：供給源別

市場概要
哺乳類
昆虫
両生類

細胞株開発市場：用途別

市場概要
バイオプロダクション
- 診断
- ワクチン製造
- 組み換えタンパク質治療薬
組織工学と再生医療
毒性試験
研究
創薬
- ターゲット検証
- 疾患モデル
- 医薬品のスクリーニングと開発

細胞株開発市場：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

American Type Culture Collection（ATCC）（US）
Corning, Inc.（US）
European Collection of Cell Cultures（ECACC）（UK）
GE Healthcare（US）
Lonza Group AG（Switzerland）
Sartorius AG（Germany）
JSR Life Sciences（US）
MERCK KGaA（Germany）
Thermo Fisher Scientific, Inc.（US）
Wuxi Apptec（China）
Celltrion, Inc.（South Korea）
Bio-Techne Corporation（US）
Charles River Laboratories International, Inc.（US）
Eppendorf AG（Germany）
Fujifilm Diosynth Biotechnologies（Japan）
Promega Corporation（US）
Danaher Corporation（US）
Thermo Fisher Scientific（US）
Perkin-Elmer（US）
Cell Culture Technologies（US）
Takara Bio Inc.（Japan）

Product Code: SQMIG35H2261

Global Cell Line Development Market size was valued at USD 4.7 billion in 2022 and is poised to grow from USD 5.16 billion in 2023 to USD 10.94 billion by 2031, growing at a CAGR of 9.84% during the forecast period (2024-2031).

The cell line development market is poised for significant growth, driven by increasing investments in innovative cell technologies and products, alongside rapid advancements in the field. A rising global demand for personalized medicine, coupled with heightened investment in cell research, is paving the way for new opportunities for providers in this sector. Furthermore, the growing need for biosimilars and biologics to address an array of diseases is expected to further enhance prospects for cell line development firms. The focus on creating novel pharmaceuticals, therapeutics, and vaccines aimed at improving healthcare outcomes is likely to stimulate demand in this area in the coming years. Additionally, the burgeoning application of gene editing technologies presents lucrative prospects for companies specializing in cell line development. However, challenges such as high development costs, ethical dilemmas, and scalability hurdles pose potential barriers to market growth throughout the forecast period and beyond. Overall, while the cell line development market faces some challenges, the convergence of technological advancements, increasing demand for advanced medical solutions, and the ongoing pursuit of innovation in healthcare are set to create a robust environment for growth and opportunity.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Line Development market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell Line Development Market Segmental Analysis

Global Cell Line Development Market is segmented by Type, Product, Source, Application, and region. Based on Type, the market is segmented into Primary Cell Lines, Continuous Cell Lines, Hybridomas, and Recombinant Cell Lines. Based on Product, the market is segmented into Equipment, and Media & Reagents. Based on Source, the market is segmented into Mammalian, Insect, Amphibian. Based on Application, the market is segmented into Bioproduction, Tissue Engineering & Regenerative Medicine, Toxicity Testing, Research, Drug Discovery. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Cell Line Development Market

The global cell line development market is driven by the escalating investments in cell research, as healthcare researchers strive to harness the intricacies of cellular functions for innovative therapeutic solutions. This emphasis on cell line development is paramount, as it underpins critical advancements in drug discovery, regenerative medicine, and personalized therapies. As researchers unlock the full potential of various cell types, the demand for specialized cell lines surges, further propelling the market. Additionally, the expanding biopharmaceutical industry seeks to capitalize on cell lines for vaccine production and bioproduction, reinforcing the significant growth prospects within this dynamic market landscape.

Restraints in the Global Cell Line Development Market

The Global Cell Line Development market faces significant restraints primarily due to the complexity and intricacy involved in developing cell lines, resulting in high operational costs. The need for advanced technologies not only escalates financial investments but also requires specialized personnel and equipment, creating barriers for entry and competition. Additionally, ensuring consistency in cell line quality presents further challenges, leading to potential delays in research and production timelines. These factors collectively contribute to heightened development expenses and may deter companies from pursuing cell line development projects, thereby impacting overall market growth and demand in this sector.

Market Trends of the Global Cell Line Development Market

The Global Cell Line Development market is experiencing a notable trend towards 3D cell culture and organoid development, driven by the increasing demand for more accurate and physiologically relevant models in drug discovery and disease research. This shift is prompting cell line development companies to innovate and refine their offerings, focusing on specialized services and products that cater to the growing need for advanced 3D culture systems. By aligning their strategies with the proliferation of organoid technologies, these companies are poised to capture substantial market opportunities and enhance their competitive edge, underscoring a significant pivot towards advanced biotechnological solutions in cell line development.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Cell Line Development Market by Type

Market Overview
Primary Cell Lines
Continuous Cell Lines
Hybridomas
Recombinant Cell Lines

Cell Line Development Market by Product

Market Overview
By Equipment
- Biosafety Cabinets
- Cell Counters & Viability Analysis Systems
- Incubators
- Centrifuges
- Bioreactors
- Storage Equipment
- Refrigerators & Freezers
- Cryostorage Systems
- Automation Systems
- Microscopes
- Filtration Systems
- Other Equipment
By Media & Reagents
- Sera
- Fetal Bovine Sera (FBS)
- Adult Bovine Sera (ABS)
- Other Animal Sera
- Media
- Minimum Essential Media (MEM)
- Reduced Serum Media
- Serum-Free Media (SFM)
- Reagents
- Supplements & Growth Factors
- Buffers & Chemicals
- Cell Dissociation Reagents
- Cryopreservative Reagents
- Other Reagents

Cell Line Development Market by Source

Market Overview
Mammalian
Insect
Amphibian

Cell Line Development Market by Application

Market Overview
Bioproduction
- Diagnostics
- Vaccine Production
- Recombinant Protein Therapeutics
Tissue Engineering & Regenerative Medicine
Toxicity Testing
Research
Drug Discovery
- Target Validation
- Disease Modeling
- Drug Screening and Development

Cell Line Development Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

American Type Culture Collection (ATCC) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Corning, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
European Collection of Cell Cultures (ECACC) (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza Group AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sartorius AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
JSR Life Sciences (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MERCK KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Wuxi Apptec (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celltrion, Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Techne Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories International, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eppendorf AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fujifilm Diosynth Biotechnologies (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Promega Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Perkin-Elmer (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cell Culture Technologies (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takara Bio Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments